- Home
- PRAX vs PDFS Comparison
PRAX vs PDFS Comparison
Compare PRAX & PDFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- PDFS
- Stock Information
- Founded
- PRAX 2015
- PDFS 1992
- Country
- PRAX United States
- PDFS United States
- Employees
- PRAX N/A
- PDFS N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- PDFS EDP Services
- Sector
- PRAX Health Care
- PDFS Technology
- Exchange
- PRAX Nasdaq
- PDFS Nasdaq
- Market Cap
- PRAX 950.8M
- PDFS 789.4M
- IPO Year
- PRAX 2020
- PDFS N/A
- Fundamental
- Price
- PRAX $59.22
- PDFS $23.79
- Analyst Decision
- PRAX Strong Buy
- PDFS Strong Buy
- Analyst Count
- PRAX 10
- PDFS 3
- Target Price
- PRAX $101.00
- PDFS $33.33
- AVG Volume (30 Days)
- PRAX 399.5K
- PDFS 297.7K
- Earning Date
- PRAX 08-12-2025
- PDFS 08-07-2025
- Dividend Yield
- PRAX N/A
- PDFS N/A
- EPS Growth
- PRAX N/A
- PDFS N/A
- EPS
- PRAX N/A
- PDFS 0.03
- Revenue
- PRAX $8,122,000.00
- PDFS $185,933,000.00
- Revenue This Year
- PRAX N/A
- PDFS $23.39
- Revenue Next Year
- PRAX $4,434.72
- PDFS $18.37
- P/E Ratio
- PRAX N/A
- PDFS $798.27
- Revenue Growth
- PRAX 270.02
- PDFS 11.75
- 52 Week Low
- PRAX $26.70
- PDFS $15.91
- 52 Week High
- PRAX $91.83
- PDFS $36.25
- Technical
- Relative Strength Index (RSI)
- PRAX 78.36
- PDFS 65.64
- Support Level
- PRAX $53.89
- PDFS $23.09
- Resistance Level
- PRAX $59.10
- PDFS $23.92
- Average True Range (ATR)
- PRAX 3.26
- PDFS 0.79
- MACD
- PRAX 0.59
- PDFS -0.05
- Stochastic Oscillator
- PRAX 88.19
- PDFS 82.14
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About PDFS PDF Solutions Inc.
PDF Solutions Inc offers products and services designed to empower engineers and data scientists across the semiconductor ecosystem to improve the yield, quality, and profitability of their products. The solutions combine proprietary software, physical intellectual property (or IP) for integrated circuit (or IC) designs, electrical measurement hardware tools, various methodologies, and professional services. The company's products and services are sold to integrated device manufacturers (or IDMs), fabless semiconductor companies, foundries, outsourced semiconductor assembly and test (or OSATs), and system houses.